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with placebo, morning PEF increased
We have undertaken a multicentre, long (difference from placebo 28 l/min, 95% CI taken on entry was kept constant throughout placebo, and not to use supplemental ter- * Doses are expressed as equipotent doses. Four patients were not classified because they were butaline for six hours before clinic visits.
using irregular doses.
At each visit (and at the same time for each subject), FEV 1 , blood pressure, and pulse rate were measured, and questions about adverse control as judged by daily peak flow measurements, symptom scores, and frequency of events were asked. The primary variable in the study was the total daily score of asthma exacerbations.
symptoms. Subjects therefore filled in daily diary cards to record daytime symptoms of chest discomfort, sputum production, cough, Methods  activity, and wheezing on a scale ranging from 0=none to 3=very severe. Night time sympTwo hundred and thirty nine adult asthmatic subjects (table 1) were studied for eight months toms of wheeze and cough were recorded on the same scale adding up to a total asthma (six months of treatment). The study was performed from June 1992 until October 1994 at symptom score of 21. From previous studies of similar design it was estimated that, with 16 centres, six in The Netherlands and 10 in Canada. Sixty five subjects in The Netherlands 100 patients in each treatment group, there was an 80% chance of detecting a true mean were recruited from 44 general practitioners to a coordinating centre and 45 from five out-difference of about 1.6 units in the change in score between the two treatment groups when patient hospital clinics. All 129 subjects in Canada were recruited from 10 outpatient hos-using a test at the 5% significance level. This was based on the assumption that the standard pital clinics.
Inclusion criteria were asthma according to deviation of the change for the total score was about 4 units. The highest of three measthe definition of the American Thoracic Society, 8 regular use of any dose of inhaled cortico-urements of peak expiratory flow (PEF) by mini-Wright peak flow meter was recorded each steroids, the use of at least five inhalations of a short acting 2 agonist per week before the morning and evening, together with use of day and night time bronchodilators and other entry visit, and >15% reversibility in baseline forced expiratory volume in one second (FEV 1 ) medication. PEF was measured before inhalation of the study drug, and the subjects were after two inhalations of 250 g terbutaline (Bricanyl Turbohaler, Astra Draco, Sweden) or asked to refrain from the use of terbutaline at least six hours before a measurement. If there the equivalent dose of salbutamol. Exclusion criteria were the use of oral corticosteroids at was a 20% drop from run-in values in morning PEF during two consecutive days, the subject any time in the last month, smoking history of >20 pack years, FEV 1 of <40% predicted, or telephoned the investigator who then initiated an oral prednisolone course for treatment of the an exacerbation of asthma symptoms during the previous month. The use of cromoglycate, exacerbation. All lung function measurements were made between 08.00 and 12.00 hours. 2 theophylline, and anticholinergic drugs was not allowed during the study.
agonists were stopped at least six hours before each test. FEV 1 was measured with a calibrated The study protocol was approved by the medical ethics committees of all participating spirometer according to standardised guidelines. 9 At least three reproducible values (<5% centres. All subjects gave written informed consent. difference) were obtained and the highest value was used in the analyses.
 
A double blind, placebo controlled, parallel    The primary variables of investigation were design was used with a run-in period of four weeks to obtain baseline values, a treatment total asthma symptom score (sum of seven items; minimum score 0, maximum score 21) period of 24 weeks, and a washout period of four weeks. The dose of inhaled corticosteroids and morning PEF recorded in diaries. PEF was steroids were used and the doses are expressed steroid. Two hundred and eight subjects completed the study. Thirteen subjects using placebo and 18 subjects using formoterol discontinued treatment measured 12 hours after the last intake of study (table 2) . Discontinuation due to deterioration drug, thus reflecting the remaining effect of of asthma was higher in the placebo group (n= formoterol. Daily means, where missing data 6) than in the formoterol group (n=1). Diswere substituted according to the last value continuation due to adverse events in the forextended principle, were used to illustrate the moterol group (n=5) was caused by tremor (3), lung function and asthma symptoms during bronchospasm (1), and rash (1). the entire study. The primary end point was the change from the run-in period (mean value over the last 14 days) to the end of the treatment   period (mean value over the last 28 days).
Results of the total symptom scores are preComparisons of the treatments were performed sented in fig 1. In the formoterol group a small using an analysis of variance model with the but statistically significant reduction in total factors treatment and centre. Run-in values symptom score occurred (difference between were used as covariates. The "all patients end of run-in period and end of treatment= treated" approach was applied. A significance 1.28) which lasted the whole treatment period level of 5% was used.
and returned to baseline values immediately after the start of the washout period (difference between run-in and washout periods=0.2).
Results
The placebo group reported a smaller change Two hundred and eighty subjects entered the in symptom scores (0.64). The difference in run-in period of the study, and 239 subjects the change in symptom scores between the two were randomised to two parallel treatment groups (0.64) was significant (p=0.039; 95% groups. Those receiving formoterol 24 g twice CI 1.23 to 0.04) and largely reflected changes daily (n=125) and placebo (n=114) had simin wheeze at night and chest discomfort. Both ilar characteristics (table 1). The mean age of of these scores changed from 0.6 (last 14 days in the subjects was 42.8 years and the duration run-in period) to 0.3 (last 28 days of treatment of asthma was 20.6 years. Mean pre-bronchoperiod) in the formoterol group, whereas the dilator FEV 1 was 67.1% of predicted normal, placebo group showed no difference. The mean and mean reversibility was 25.7% at baseline.
(SD) change in the total symptom score during The dose of inhaled corticosteroids ranged treatment with formoterol was −1.6 (2.6) in from 100 g to 3200 g daily. Many kinds of the low dose steroid group (Ζ400 g) and −1.1 (2.9) in the high dose steroid group ([1600 g).
  ()
Mean morning and evening PEF during the study are shown in fig 2. The mean changes in morning and evening PEF values from the last two weeks of the run-in period to the last four weeks of the treatment period were 25.9 l/ min (morning) and 21.2 l/min (evening) in the formoterol group and −2.1 l/min (morning) and −5.9 l/min (evening) in the placebo group. The mean difference between the two groups was highly significant (morning PEF 28 l (95% CI 18 to 38), p<0.001; evening PEF 27.1 (95% CI 17 to 37), p<0.001) and remained stable during the 24 weeks of treatment. Mean (SD) morning peak flow in the formoterol group was 391.6 (99.3) l in the last 14 days of the runin period, and 393.4 (107.1) l in the washout period. Placebo values were 382.0 (101.4) l and 383.9 (103.5) l, respectively. The mean improvement in morning peak flow in the formoterol group was independent of the dose of inhaled steroid (Ζ400 g, 31.3 l; [1600 g, 32.8 l), the difference being not statistically Figure 1 Daily mean total symptom scores before, during, and after treatment with formoterol or placebo.
significant (p=0.55).
 
The number of courses of oral prednisolone used during the treatment period provided an indication of the total number of asthma exacerbations. Thirty two (28.1%) of the 114 subjects in the placebo group had 55 prednisolone courses and 33 (26.4%) of the 125 subjects in the formoterol group had 58 courses. The difference between the two groups was not statistically significant.
Discussion
The effect of adding inhaled formoterol, 24 g twice daily, to inhaled corticosteroids in the treatment of asthmatic subjects was superior to placebo. Subjects treated with formoterol improved according to every variable in the study (daily symptom scores, PEF, requirement of additional bronchodilator use for symptom relief, and FEV 1 ) independently of steroid dose. The reported effects on PEF and FEV 1 were measured 12 hours after the intake of for- to a reduction in response would be noticed first on these effects, we did not find a reduction in response in any of the clinical variables tested, nor a worsening of asthma during the six months of treatment with formoterol. The mean difference in symptom scores between  1 Mean (SD) FEV 1 at the start of the treatment formoterol and placebo remained small but stable. Only six subjects discontinued the study period was 2.38 (0.77) l in the formoterol group and 2.21 (0.79) l in the placebo group. The because of asthma deterioration, five of them in the placebo group. mean FEV 1 in the formoterol group changed from 2.38 l at baseline to 2.57 (0.85) l after These results are consistent with the benefits seen in several other long term studies with four weeks of treatment and to 2.51 (0.85) l after 24 weeks of treatment. In the placebo long acting 2 agonists.
10-13 None of the studies has shown substantive evidence that treatment group the mean FEV 1 changed from 2.21 (0.79) l to 2.26 (0.82) l after four weeks with long acting 2 agonists has deleterious effects on asthma control. The available long of treatment and to 2.25 (0.84) l at the end of the treatment period. The change in FEV 1 from term studies show maintenance of a constant bronchodilating effect and symptom control. baseline was consistently larger with formoterol than placebo, the difference in the change be-In a multicentre study with 301 subjects Hekking et al 13 compared formoterol (12 g inhalatween the groups being 0.18 l (95% CI 0.08 to 0.28) at week 8, 0.11 l (95% CI 0.00 to 0.21) tion twice daily) with salbutamol (200 g inhalation four times daily) for 12 weeks. The at week 16, and 0.12 l (95% CI 0.02 to 0.22) at week 28. At the end of the washout period mean morning PEF in the formoterol group was 37 l/min higher than in the salbutamol (week 32) there was no difference in the FEV 1 between the two groups. There were no in-group, and the mean numbers of recorded asthma attacks per week were 1.7 and 2.8, dications of a difference in FEV 1 over time between the two treatment groups (p=0.21). respectively, the difference being statistically significant. In another study by Kesten and coworkers 14 inhaled formoterol in a dose of 12 g twice daily provided better symptomatic con-  The mean daytime use of rescue medication trol of asthma accompanied by reduced diurnal variation in PEF than inhaled salbutamol in a (terbutaline 250 g) in the formoterol treatment group decreased by 1.5 inhalations from dose of 200 g four times daily in a three month double blind study. In a 12 month follow up run-in (mean 2.4) to treatment (mean 0.9) and returned to baseline values after the beginning study the improvements in asthma control and lung function were maintained at the levels of the washout period (mean 2.2). Mean night time rescue medication use decreased by 0.9 reached in the three month study.
11 Studies with another long acting 2 agonist, salmeterol, inhalations from 1.5 to 0.6 with a smaller decrease in the placebo group (−0.4 and −0.2, reported similar findings.
15 16 A recent report on the effects of added salmeterol in subjects respectively). The difference between the two groups was highly significant (daytime −1.1 already treated with inhaled corticosteroids 10 showed better symptom control and higher (95% CI −1.4 to −0.7), p<0.001; night time −0.8 (95% CI −1.0 to −0.5), p<0.001) and mean morning and evening PEF in the salmeterol treated group than in the group treated remained stable throughout the treatment period.
with increased doses of corticosteroids. In a
